Preizkusite novo različico: COBISS+
 Vzajemna baza podatkov: COBIB.SI - Vzajemna bibliografsko-kataložna baza podatkov (Štev. zapisov: 5.072.698)

Izbrani zapis trajna povezava

AvtorFranić, Damir
Naslov Nadomestno hormonsko zdravljenje - kje smo danes? = Hormone replacement therapy - where are we today? / Damir Franić
Vrsta/vsebinatype of material prispevek na konferenci
Jezikslovenski
Leto2005
Fizični opisStr. 65-72
Opombe37 ref.
BSDOCID114616
Predmetne oznakeMenopause
Estrogen Replacement Therapy
Postmenopause
Osteoporosis
Breast Neoplasms
Cerebrovascular Disorders
Coronary Disease
Pulmonary Embolism
Dojka, novotvorbe
Estrogen, nadomestno zdravljenje
Menopavza
Osteoporoza
Pomenopavza
Cerebrovaskularne motnje
Koronarna bolezen
Pljučna embolija
PovzetekPopulation are getting older and older worldwide, so postmenopausal women willsurvive one third of her life during the postmenopausal period. Therefore,they have to be aware regarding quality of life during that period. Since the sixties year of the last century, HRT seemed to be a gold standard for preventive as well as therapeutic strategies in solving the postmenopausalcomplains. Most of the epidemiological and observational studieshave shown that HRT was useful not only in therapy of short-term consequences of menopause (neurovegetative complains), but also in therapy of long-term consequences (osteoporosis, cardiovascular disease). Randomized clinical trials, WHI have been the most important, were taken place in the last decade of the evidence based medicine era. WHI study excluded radioprotection effect of the HRT, emphasized its influence on breast cancer risk, showing the apparent increase of tromboembolic events, strokes, coronaryheart diseases and in the same time decreased risks of colon cancer and osteoporotic fractures. Unfortunately, WHI study included an old women (63years in average), on the same therapeutic regimen, mostly have been not healthy, some of them were overweight, some of them were even obese and used another drugs. Therefore the results of the WHI study were inconvinient for the clinical practice. According that, all leading menopausal societies worldwide, recommended a new guidelines for the hormone treatment of the postmenopausal women. HRT remains the therapy of choice for the treatment of climacteric syndrome, prevention and therapy of urogenital syndrome and premature menopause, and prevention of osteoporosis of perimenopausal and early postmenopausal women, as well.
COBISS.SI-ID19554009
Glej publikacijo TI=Kakovostna obravnava bolnika v družinski medicini : izbrana poglavja s področja vodenja bolnika z rakom, bolečino, psihiatrija, ginekologija, angiologija, gastroenterologija in delavnice : 31. srečanje, Ljubljana, 27. in 28. maj 2005.- Str. 65-72